There has been an abundance of ADHD neurofeedback (NF) studies in the past decade in an effort to show NF’s efficacy on reducing the cardinal symptoms of ADHD. A recent meta-analysis concluded that NF was an efficacious treatment of ADHD, with a large effect size for inattention and impulsivity and a medium effect size for hyperactivity. Most studies, including the ones in the meta-analysis, have used a wait-list or active control as comparison groups. More recently, there have been a few NF studies using a blinded placebo-controlled design. These studies have shown equivocal results, indicating NF and placebo NF produced similar outcomes.
In our randomized double-blind placebo-controlled study we found no significant differences between conditions on parent and teacher ratings, and children’s IVA scores. However, when EEG learning was used as a moderating variable there were significant differences between groups for the teacher ratings and IVA scores. This presentation will review the ADHD NF research highlighting studies using placebo as a comparison, and how learning to change EEG can impact results in a NF placebo-controlled study of ADHD children.
In the 1990s Prof. Yuri Kropotov started his research in the field of quantitative EEG and evoked potentials in normal subjects, in ADHD population and in neurological patients to whom intracranial electrodes were implanted for diagnosis and therapy.
Since the first reports of neurofeedback treatment in ADHD in 1976 many studies have been carried out investigating the effects of neurofeedback on different symptoms of ADHD such as inattention, impulsivity and hyperactivity. This technique is also used by many practitioners, but the question as to the evidence-based level of this treatment is still unclear.
Phenotype evaluation of the EEG was proposed in a paper in 2005 published in Clinical Electroencephalography and Neurophysiology. The retrospective analysis of many decades of experience has since been actively evaluated, from published works focusing on basic neuroscience (J. Pop-Jordanov), and the work from Holland on medication response prediction (M. Arns).
Professor Yuri Kropotov demonstrates that by knowing which brain dysfunction is associated with symptoms of ADHD a clinician can suggest the individualised treatment, whether it be medication, neurofeedback, tDCS or GABA agonists.
This paper is an exploration of the theoretical grounds of resilience and hope. In our previous work with women who mother children with ADHD or ASD we found that many women are themselves disabled by their child's disability; they are isolateresild, marginalised and silenced (Carpenter & emerald 2009; Carpenter & Austin 2007). Yet, these women persevere in the face of the ongoing challenges of mothering a child with a disability. We now ask: is this resilience they show, or hope or is it something else again?
This research is the first to demonstrate that Neurotherapy resulted in the dynamic neuromodulation of the dopamine-mediated frontal and norepinephrine-mediated parietal components of the attentional system, as proposed by Tucker and Williamson’s (1984) model of the attentional system. It provides further support to the recent controlled studies and meta-analysis that suggest that Neurotherapy is an effective and efficacious treatment for ADHD.